Impaired intravascular triglyceride lipolysis constitutes a marker of clinical outcome in patients with stable angina undergoing secondary prevention treatment A long-term follow-up study by Sposito, Andrei C. et al.
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OBJECTIVES We sought to verify whether the intravascular metabolism of chylomicron-like emulsion may
predict the clinical evolution of patients with coronary artery disease (CAD) undergoing
secondary prevention therapy of CAD.
BACKGROUND Case-control studies have suggested an association between impaired intravascular catabolism
of triglyceride (TG)-rich lipoproteins and CAD. However, evidence is lacking with respect
to the potential clinical relevance of this metabolic disorder in CAD patients.
METHODS During a period of 4.5  0.9 years, we followed up 63 stable CAD patients (mean age 60 
10 years) undergoing secondary prevention therapy (low-density lipoprotein cholesterol100
mg/dl) in whom kinetic studies of the in vivo catabolism of chylomicron-like emulsions were
performed. At enrollment into the study, fasting patients were injected intravenously with a
chylomicron-like emulsion labeled with radioactive triglyceride (3H-TG) and cholesteryl
esters (14C-CE) to evaluate the efficacy of intravascular TG lipolysis.
RESULTS At baseline, CAD patients displayed a diminished fractional clearance rate (FCR) for 3H-TG
(26%; p 0.027), for 14C-CE (37%; p 0.015), and for delipidation index (DI) (26%;
p  0.02) as compared with 35 control subjects. During follow-up of secondary prevention
therapy, 33% of CAD patients (n  21) presented with clinically refractory angina and
aggravated coronary angiographic severity. The FCR for 3H-TG (44%; p  0.005) and DI
(41%; p  0.006) in those patients with refractory angina was significantly lower than that
observed in those with stable evolution. Moreover, in a Cox multivariate regression analysis,
the presence of a DI less than the median value was an independent predictor of an
unfavorable clinical evolution (adjusted hazard ratio 3.32; 95% confidence interval 1.21 to
9.14; p  0.020).
CONCLUSIONS The current study establishes that delayed intravascular TG lipolysis is a strong and
independent predictor of evolution to severe angina among patients undergoing secondary
prevention therapy of CAD. (J Am Coll Cardiol 2004;43:2225–32) © 2004 by the
American College of Cardiology Foundationo
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rntravascular lipolysis is the rate-limiting step for the
ydrolysis and removal of triglyceride (TG)-rich lipopro-
eins, chylomicrons, and very low-density lipoproteins
See page 2233
VLDL) from the circulation (1,2). Lipoprotein lipase
LPL) is the key enzyme that acts at the endothelial surface
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cids from TG-rich lipoproteins for uptake by cells of
eighboring tissues for either energy production or storage.
elayed intravascular lipolysis increases the exposure of
rterial wall cells to atherogenic TG-rich lipoproteins,
hereby favoring their accumulation within the subendothe-
ial space. In case-control studies with a chylomicron-like
mulsion model, we have observed that patients with
oronary artery disease (CAD) exhibit delayed intravascular
G lipolysis as compared with subjects without angio-
raphically detectable CAD (3,4). In a recent meta-analysis,
arriers of the Gly188Glu, Asp9Asn, and Asn291Ser amino
cid-changing mutations in LPL displayed an increased risk
f CAD as compared with non-carriers, which may indicate
hat an impaired intravascular lipolysis could influence the
isk of CAD (5). However, evidence to establish the
otential clinical impact of impairment in intravascular TG
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herapy is lacking.
Large clinical trials have shown that cholesterol-lowering
reatment with statins reduces total mortality among sub-
ects undergoing primary and secondary prevention therapy.
e and others have shown that statin treatment increases
he fractional clearance rate (FCR) of native low-density
ipoprotein (LDL) and chylomicron-like emulsions via the
DL receptor-dependent pathway (6,7). However, as ex-
ected, statins had no effect on the rate of intravascular
ipolysis of TG-rich lipoproteins (6,7). Thus, this study was
esigned to evaluate the clinical impact of such delayed
ntravascular TG lipolysis in CAD patients who were
reated with statins. Our findings indicate that impaired
ntravascular TG lipolysis has a long-term impact on clinical
nd angiographic progression of patients with chronic stable
AD.
ETHODS
atients. Between January 1994 and March 1996, 63
atients with CAD (14 women; age range 43 to 70 years)
ere admitted to the Lipid Research Laboratory of the
eart Institute (Sa˜o Paulo, Brazil) for determination of the
lasma decay curves of doubly radiolabeled chylomicron-
ike emulsions. Patients originally had been referred to the
utpatient Clinic of the Heart Institute for clinical man-
gement of stable angina and had CAD confirmed by
oronary angiography performed 6 months before entry
nto the study. Inclusion criteria were plasma TGs 400
g/dl and no use of lipid-lowering therapies during the two
onths preceding enrollment. Subjects with diabetes, those
ho had high alcohol intakes (1 drink per day), or those
ho had liver, renal, thyroid, inflammatory, or neoplastic
iseases were not included in the study. Equally, patients
ith heart failure or severe angina as defined by functional
lass III or IV were excluded. All enrolled women were
Abbreviations and Acronyms
ACAD aggravating coronary artery disease
ACE  angiotensin-converting enzyme
CAD  coronary artery disease
CE  cholesterol ester
CI  confidence interval
DI  delipidation index
FCR  fractional clearance rate
HDL  high-density lipoprotein
HR  hazard ratio
LDL  low-density lipoprotein
LPL  lipoprotein lipase
SCAD  stable coronary artery disease
TG  triglyceride
VLDL  very low-density lipoproteinequired to be postmenopausal, and none were treated with tormonal replacement therapy either before or during the
tudy.
For comparison with the group of CAD patients, the
mulsion plasma decay curve was also determined in 35
ontrol subjects (8 women; age range 42 to 71 years). No
ontrol subjects were using lipid-lowering drugs, and the
ata used for this comparison were obtained before the
AD patients were entered into secondary prevention
reatment. Normal angiographic examination was necessary
or study inclusion of control subjects, and even mild
uminal irregularities were considered an exclusion criterion.
oronary angiographies were performed 6 months before
nrollment to investigate thoracic pain; control and non-
AD subjects were selected to be comparable on the basis
f age, gender, and TG levels. Written, informed consent
as obtained from all subjects before entry into the study,
nd the experimental protocol was approved by the Ethical
nd Scientific Committee of the Heart Institute in accor-
ance with the Declaration of Helsinki.
mulsion clearance study. The chylomicron-like emul-
ion (final composition: triolein 76.5  4.1%, free choles-
erol 1.9  0.3%, cholesteryl oleate 11.2  3%, and
hosphatidylcholine 10.4 1.3%; size range from 80 to 110
m) was made from lipid mixtures emulsified by ultrasonic
rradiation and purified by ultracentrifugation in density
radients as described previously (3,4,6,8). 14C-cholesteryl
leate and 3H-triolein (Amersham, Buckinghamshire,
nited Kingdom) were added to the lipid mixtures for the
etermination of plasma kinetics. The emulsion was steril-
zed by passage through a 0.2-m filter and 3 to 5 mg of
otal lipid emulsion (200 to 300 l) containing 74 kBq (2
Ci) of the 14C and 148 kBq (4 Ci) of the 3H label were
njected.
Enrolled patients reported to the laboratory by 8:00 AM
fter a 12-h overnight fast, and blood was collected for lipid
nd apolipoprotein analysis, as described in the following
ext. The radiolabeled emulsion was then injected in a bolus
200 to 300 l) into the antecubital vein. To obtain blood
amples for radioactivity measurement, the antecubital vein
f the contralateral arm was cannulated and slow infusion of
/saline, without heparin, was started to maintain catheter
atency. The total saline volume infused did not exceed 100
l. Blood samples were collected at pre-established inter-
als of 2, 4, 6, 10, 15, 20, 30, 45, and 60 min after injection
f the emulsion. Blood was collected and radioactivity in the
amples was determined using a Packard 1660 TR Spec-
rometer (Packard, Meriden, Connecticut). The curve cal-
ulations of the plasma decay of 14C and 3H radioactivity
ere made by the non-linear least squares method, as
escribed previously (3,4,6,8–10), and were expressed as the
CR of both radioactive labels. Redgrave and Zech (11)
reated the delipidation index (DI), which corrects total TG
isappearance (lipolysis plus particle uptake) for cholesterol
ster (CE) disappearance (particle uptake only). Thus, the
I provides a good estimate of TG lipolysis from plasma byhe following formula:
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The calculated interassay coefficient of variation for both
mulsion label kinetic studies was 3%. The radiological
ose injected as emulsion label was evaluated according to
he guidelines of the International Commission on Radio-
ogical Protection and was below the Annual Limit for
ntake of Radionuclide (50 mSv) as previously discussed
3,4,6,8). For each chylomicron-like emulsion kinetic study,
he radioactive dose for 14C-CE and 3H-TG was 0.02 mSv
nd 0.0012 mSv, respectively.
lasma lipid and apolipoprotein determinations. Blood
amples were collected on tubes containing ethylenediamine
etraacetic acid and centrifuged at 1,500 g for 10 min at 4°C
o separate plasma. All lipid determinations were measured
irectly on plasma samples. Plasma total cholesterol and
Gs were determined using enzymatic methods (Roche
aboratories, Basel, Switzerland). High-density lipoprotein
HDL) cholesterol determination was performed by the
ame method as for total cholesterol after LDL and VLDL
recipitation with magnesium phosphotungstate. Very low-
ensity lipoprotein cholesterol and LDL cholesterol were
stimated by the Friedewald formula.
linical follow-up. After the baseline emulsion plasma
ecay study and biochemical determinations, CAD patients
eceived maximal antianginal and secondary prevention
herapies, and were clinically followed up for 4.5 0.9 years
t the Outpatient Clinic of the Heart Institute. Before
ntrance (60 days) and during the study, all patients were
n the National Cholesterol Education Program (NCEP)
ype I diet. No educational program was offered to these
atients during the study to increase physical activity.
atients were treated with standardized medical therapy
ith aspirin (100 mg/day), selective beta-blockers, and
sosorbide dinitrate (120 mg/day). The beta-blocker dosage
as individually established to obtain a heart rate between
0 and 60 beats/min. When indicated, hypertensive patients
ere also treated with calcium antagonists and/or
ngiotensin-converting enzyme (ACE) inhibitors. Treat-
ent with statins was initiated in all CAD patients. Statin
osage was also established individually, with the aim of
aintaining plasma LDL cholesterol concentrations 100
g/dl according to the NCEP-Adult Treatment Panel II
uidelines. After six weeks of treatment, the emulsion
lasma decay study was re-evaluated in a subset of enrolled
atients and is published elsewhere (6,12). Patients were
eviewed at regular intervals of four to six months by clinical
valuation and by biological analyses. Neither the patients
or trial participants, including the attending physicians,
ad any knowledge of the results of the chylomicron-like
mulsion kinetics during the study. Angina symptoms were
raded according to severity from I to IV as defined by the
anadian Cardiovascular Society. Unstable angina was de-
ned as chest pain at rest lapsing more than 10 min with
ocumented transient ST-segment depression or ST-egment elevation of 0.1 mV in at least two continuous
lectrocardiographic leads. During the follow-up, two
roups of patients were identified:
Aggravating coronary artery disease (ACAD) group—
those who evolved to functional class III or IV angina
despite the maximal dose of antianginal treatment and
were considered as displaying clinically refractory
angina. These were then submitted to a new coronary
angiography and to a revascularization procedure
when indicated.
Stable coronary artery disease (SCAD) group—those
whose functional class of angina was unchanged
during the follow-up study.
oronary angiography. Coronary angiography and left
entriculography were performed according to standard
echniques. Lumen narrowing 70% was considered as a
ignificant stenosis. All coronary angiographies were also
lassified by the Gensini score method. Severe angiographic
rogression was defined according to the following condi-
ions: 1) the appearance of a coronary stenosis 50% at the
nal angiogram in a vessel segment with no apparent
oronary stenosis at the initial coronary angiogram; 2) the
ppearance of a coronary stenosis 70% at the final angio-
ram in a vessel segment with stenosis 50% at the initial
oronary angiogram; or 3) the appearance of a new coronary
cclusion.
chocardiography. Echocardiographic evaluation was per-
ormed annually to detect possible silent deteriorations in
entricular function. M-mode and two-dimensional echo-
ardiography were performed using commercially available
achines (ATL Apogee CX and ATL Ultramark 9 HDI
V, Advanced Technology Laboratories, Bothell, Wash-
ngton) with a 2- to 4-MHz broad-band transducer. The
eft ventricular ejection fraction and segmental ventricular
otion were compared between patient groups.
tatistical analysis. Data are expressed as mean  stan-
ard deviation, and values of p 0.05 were considered to be
on-significant. The Kolmogorov-Smirnov normality test
as applied to evaluate all quantitative variables. Frequen-
ies in the categorical data were compared by the Fisher
xact test. Univariate analyses were performed by the paired
r unmatched t test for parametric data and by the Wil-
oxon signed rank test or the Mann-Whitney U test for
on-parametrical data. The correlation analysis was per-
ormed by the Spearman correlation test. The Kaplan-
eier time-to-event (clinically refractory angina) technique
nd the log-rank test were performed to compare the two
roups of CAD patients with a DI greater than or less than
he median. The Cox proportional hazards regression anal-
sis using a model built by forward stepwise selection of
ariables was performed to obtain the hazard ratios (HRs)
nd 95% confidence interval (CI). The SPSS version 8.0 for
indows (Chicago, Illinois) was used to perform statistical
alculations.
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aseline characteristics of CAD patients and controls.
able 1 shows the baseline biological and clinical charac-
eristics of CAD patients compared with control subjects.
here was no significant difference between the two groups
n age, body mass index (BMI), frequency of hypertension,
hysical inactivity, smoking habit, ex-smoking habit, or
ean plasma levels of TGs, total cholesterol, LDL choles-
erol, and VLDL cholesterol. High-density lipoprotein
holesterol was 14% lower (p  0.012) in the CAD group
han in the control group.
Consistent with our previous results, the FCR for
H-TG was 26% lower (p  0.027) and the FCR for
4C-CE was 37% lower (p 0.015) in the CAD group than
n the control group (Table 1). To minimize the influence of
he uptake of the chylomicron-like particles from the
irculation on the plasma decay of 3H-TG, we calculated
he DI, which expresses the amount of emulsion TG
emoved exclusively by lipolysis before the chylomicron-like
mulsion is removed from plasma. Patients in the CAD
roup had a 26% lower DI than the control group (p 
.02) (Table 1). High-density lipoprotein cholesterol was
ositively correlated with FCR for 3H-TG (r  0.4; p 
.001) and DI (r  0.6; p  0.001).
linical follow-up. Complete clinical follow-up was per-
ormed in all enrolled patients. After the 4.5  0.9 years of
he follow-up period that ensued the emulsion plasma decay
tudy, 21 patients (33%) displayed clinically refractory
ngina (ACAD group) and 42 (67%) had a stable clinical
volution (SCAD group). At enrollment and before treat-
ent, all CAD patients had class I or II angina, and the
requency of patients with class I and II was similar in the
CAD and SCAD groups (class I: ACAD, n  6 and
CAD, n 9; class II: ACAD, n 15 and SCAD, n 33;
Table 1. Baseline Characteristics, Plasma Lipid
Emulsion Radioactive Lipids of the Study Sub
Angiographically Defined CAD
Without
Number of subjects 35
Age (yrs) 61 
Male gender, n (%) 27 (77
BMI, kg/m2 27 
Hypertension, n (%) 14 (40
Physical inactivity, n (%) 15 (42
Smoking habit, n (%) 5 (15
Ex-smoking (1 yr), n (%) 7 (20
Total cholesterol, mg/dl 236 
Triglycerides, mg/dl 144 
VLDL cholesterol, mg/dl 29 
LDL cholesterol, mg/dl 156 
HDL cholesterol, mg/dl 49 
FCR cholesterol esters, min1 0.0185 
FCR triglycerides, min1 0.0348 
Delipidation index 0.66 
BMI  body mass index; CAD  coronary artery disease; F
LDL  low-density lipoprotein; NS  not significant; VLDNS). The mean anginal class at study initiation was also 0imilar in the two groups (ACAD 1.7  0.5 vs. SCAD 1.8
0.5; p  NS) but became different at the end of the
ollow-up despite maximal antianginal therapy (ACAD 3.3
0.5 vs. SCAD 1.7  0.6; p  0.0001). Neither an acute
ardiovascular event nor detrimental evolution of systolic
entricular function, as assessed by the segmental ventricular
otion or ejection fraction of the left ventricle (Table 2),
as documented during the follow-up. The mean follow-up
ime was similar in both groups (Table 2).
As shown in Table 2, there was no significant difference
n age, BMI, the frequency of hypertension, physical inac-
ivity, smoking habit, or ex-smoking habit between the
CAD and SCAD groups. During the follow-up, there
as no significant modification in the frequency of these
isk factors in the two groups. Equally, after statin treat-
ent, mean plasma concentrations of total cholesterol (170
23 mg/dl vs. 162  29 mg/dl; p  NS), TGs (149  81
g/dl vs. 140  72 mg/dl; p  NS), VLDL (30  16
g/dl vs. 28  14 mg/dl; p  NS), LDL (96  9 mg/dl vs.
4  11 mg/dl; p  NS), and HDL cholesterol (45  10
g/dl vs. 44  8 mg/dl; p  NS) were not significantly
ifferent between the ACAD and SCAD groups, respec-
ively. The effect of statin treatment to increase FCR-CE
70%; p  0.01) and the absence of significant effect on
CR-TG or DI was confirmed in a subset of enrolled
atients and was published elsewhere (6,12). There was no
ifference between the two groups in the use of calcium
ntagonists or ACE inhibitors.
Figure 1 shows the disappearance curves for mean plasma
H-TG and 14C-CE in the ACAD group, SCAD group,
nd control group. The time-course curves revealed a slower
ecay in the circulating levels of 3H-TG in the ACAD
roup. In fact, the ACAD group had a significantly lower
ean FCR-TG (44%, p  0.005) and DI (41%, p 
d Apolipoproteins and Plasma FCR of the
According to the Presence or Absence of
With CAD p Value
63
60  10 NS
43 (68%) NS
27  4 NS
24 (38%) NS
32 (51%) NS
11 (17%) NS
11 (17%) NS
225  46 NS
155  75 NS
31  15 NS
152  36 NS
42  9 NS
7 0.0117  0.0116 0.015
7 0.0256  0.0213 0.027
0.49  0.33 0.02
fractional clearance rate; HDL  high-density lipoprotein;
very-low-density lipoprotein.s, an
jects
CAD
9
%)
3
%)
%)
%)
%)
27
54
10
38
14
0.012
0.016
0.25
CR .006) than the SCAD group, thereby indicating a greater
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atients who displayed aggravation of angina status (Table
). There was no difference in the mean FCR-CE between
he two groups (Table 2).
To estimate the relative risk of the delayed intravascular
G lipolysis, we divided the enrolled CAD patients in two
ubgroups with a baseline DI greater than or less than the
edian. The Kaplan-Meier analysis revealed that patients
ith DI less than the median had the highest probability of
eveloping refractory angina during the follow-up period
han patients with a DI greater than median (log rank 95%
I 1.39 to 8.24; p  0.007) (Fig. 2). The Cox proportional
azards regression model was fitted to obtain the HR for
he clinical evolution to refractory angina, and the analysis
as adjusted for the confounding effects of: post-statin-
reatment LDL cholesterol; age; gender; BMI; the presence
f clinical risk factors such as hypertension, physical inac-
ivity, smoking or ex-smoking habit; and the use of calcium
ntagonists or ACE inhibitors. A final model was built by
orward stepwise selection of variables, and a DI lower than
he median was the only variable identified as an indepen-
ent predictor of evolution to clinically refractory angina
adjusted HR 3.32; 95% CI 1.21 to 9.14; p  0.020). None
f the other variables, including HDL cholesterol (adjusted
R 0.96; 95% CI 0.86 to 1.11; p  0.8), was selected for
he model. A second modeling using categorical variables
omposed of statins and their dosages, beta-blockers and
heir dosages, ACE inhibitors and their dosages, and
Table 2. Clinical and Kinetic Characteristics o
Patients Who Had SCAD
Angina Evolution AC
Number of subjects 21 (
Duration of follow-up, yrs 4.4 
Age, yrs 62 
Age at diagnosis of CAD, yrs 56 
BMI, kg/m2 26 
Hypertension, n (%) 7 (
Physical inactivity, n (%) 9 (
Smoking habit, n (%) 4 (
Ex-smoking (1 yr), n (%) 5 (
CAD familial history, n (%) 4 (
Angina functional class
Baseline 2.1 
End of follow-up 3.2 
Left ventricular ejection fraction
Baseline 0.70 
End of follow-up 0.69 
Baseline coronary angiography
One-vessel disease, n (%) 18 (
Two-vessel disease, n (%) 2 (
Three-vessel disease, n (%) 1 (
Gensini score 60 
FCR-cholesterol esters, min1 0.0071 
FCR of triglycerides, min1 0.0165 
Delipidation index 0.33 
ACAD  aggravating coronary artery disease; SCAD  staalcium blockers and their dosages, as potential predictors— plus all the other variables mentioned previously—gave the
ame final model.
ngiographic analysis. At the initial coronary angiogra-
hy, there was no difference between the ACAD and
CAD groups either in the frequency of patients with one-,
wo-, or three-vessel disease or in the angiographic score
Table 2). Because all of the ACAD patients had been
ubmitted to angiographic re-evaluation, we compared the
aseline and final angiographies of these patients in order to
erify the presence of angiographic progression. Indeed, all
f the patients in the ACAD group exhibited angiographic
rogression as indicated by the increase in the Gensini
ngiographic score (69  6%; p  0.013). Nevertheless, we
pplied a very strict criterion, as defined in the Methods
ection, with the aim of comparing the kinetic data between
he two groups of patients with a marked difference in
ngiographic progression. By this criterion, in the ACAD
roup, 11 patients (52%) presented with severe angiographic
rogression and 10 patients presented with non-severe
rogression. There was no difference in age (62  9 vs. 61
10; p  NS), BMI (27  3 vs. 26  3; p  NS),
requency of hypertension [3 (30%) vs. 4 (36%); p  NS],
hysical inactivity [4 (40%) vs. 5 (45%); p  NS], smoking
abit [2 (20%) vs. 2 (18%); p  NS], mean total cholesterol
169  20 mg/dl vs. 173  24 mg/dl; p  NS), TGs (148
83 mg/dl vs. 149  72 mg/dl; p  NS), VLDL
holesterol (29  19 mg/dl vs. 28  14 mg/dl; p  NS),
DL cholesterol (95  10 mg/dl vs. 96  8 mg/dl; p 
S), or HDL cholesterol (45  8 mg/dl vs. 44  9 mg/dl;
ients Who Experienced ACAD and of
SCAD p Value
42 (67%)
4.5  0.7 NS
60  10 NS
55  9 NS
27  4 NS
17 (40%) NS
23 (55%) NS
7 (17%) NS
6 (14%) NS
26 (62%) NS
2.0  0.6 NS
1.9  0.7 0.001
5 0.69  0.05 NS
7 0.68  0.09 NS
35 (83%) NS
5 (12%) NS
2 (5%) NS
72  53 NS
069 0.0115  0.0099 NS
072 0.0297  0.0240 0.005
8 0.56  0.32 0.006
ronary artery disease; other abbreviations as in Table 1.f Pat
AD
33%)
1.0
10
9
4
33%)
43%)
20%)
24%)
67%)
1.2
0.8
0.0
0.0
86%)
9%)
5%)
55
0.0
0.0
0.2 NS) between the subgroups with severe versus non-
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Intravascular Lipolysis and Stable Angina Outcome June 16, 2004:2225–32evere angiographic progression, respectively. However, as
hown in Table 3, FCR-TG was 35% smaller (p  0.026)
nd DI was 40% smaller (p  0.04) in the group of patients
ith severe angiographic progression, suggesting an associ-
tion between the impairment of intravascular TG lipolysis
nd severity of angiographic progression. No difference
as observed in FCR-CE between these two subgroups
Table 3).
ISCUSSION
he present long-term follow-up study reveals for the first
ime that an impaired rate of intravascular TG lipolysis is a
trong and independent predictor of unfavorable clinical
utcome in statin-treated patients with SCAD. In addition,
mong patients who presented with clinically refractory
igure 1. Plasma disappearance curves of the emulsion 3H-triglyceride
TG) (A) and 14C-cholesteryl ester (CE) (B) determined in the controls, in
atients who presented clinical aggravating coronary artery disease
ACAD), and in those who had evolution of stable coronary artery disease
SCAD).ngina, the impairment in TG lipolysis was related to the segree of coronary lesion progression. This finding provides
vidence to support the concept that the intravascular
ipolysis rate is implicated in the prognosis of patients with
AD.
Estimation of lipolytic activity has long been made by the
ssay of post-heparin lipase activity in vitro, whereby a large
mount of LPL released from tissue-binding sites is incu-
ated with labeled TG-rich emulsions or lipoproteins to
etermine the catabolic rate. This technique may well
valuate the functionality of LPL or hepatic lipase but does
ot reflect intravascular lipolysis activity in vivo. The access
f TG-rich lipoproteins to LPL, for example, might be
ontrolled by capillary blood flow. In line with this assump-
ion, the injection of heparin causes a rapid and transitory
eduction of plasma TG levels, thereby indicating that the
vailability of LPL is significantly increased after heparin
njection (13,14). Moreover, there is a very weak correlation
etween post-heparin plasma LPL protein and activity and
LDL TG concentration (r0.3; p 0.05) (15). In this
ontext, we also observed a weak association between
ost-heparin lipase activity and DI (r  0.35; p  0.015),
uggesting that modulation of intravascular lipolysis in vivo
s not measured in the assay in vitro (R. Santos, unpublished
ata, 2003). Kinetic analysis of the intravascular catabolism
f chylomicron-like emulsions provides a high-resolution
iew of TG-rich particle metabolism in the circulation. It
as been consistently demonstrated that chylomicron-like
mulsions compete with native chylomicrons and VLDL for
he same lipolytic mechanisms and hepatic receptor sites in
dose-dependent manner in both animal models and
uman subjects (3,16–20). As for native chylomicrons,
mulsion particles undergo a two-step metabolic process,
hich is mediated by acquired apolipoproteins such as
poCII and apoE (i.e., extensive lipolysis by LPL and rapid
ptake of remnants by the liver). Spleen uptake is negligible,
ndicating that emulsion remnants are not removed to a
igure 2. Kaplan-Meier curves of the time elapsed to a refractory angina
vent in the two groups of patients with delipidation index (DI) above or
elow the median. CI  confidence interval.ignificant degree by non-physiological routes such as the
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er of cholesteryl ester from the emulsion to native lipopro-
ein classes by cholesteryl ester transfer protein is minimal:
0 min after the injection 3% of the emulsion cholesteryl
sters are found out of the 1.006 g/ml density fraction that
orresponds to the emulsion density (3,10). Moreover, the
mulsions are composed of homogenous preparations of
articles in the size range of small lymph chylomicrons, and
he removal of remnants is independent of size within the
article size range of the emulsion preparation (21). Thus,
he kinetics of 3H-TG should reflect the combined impact
f overall intravascular lipolysis activity in vivo and TG-rich
ipoprotein uptake, whereas the DI should reflect TG
ipolysis alone.
Consistent with our previous results (3,4), the enrolled
AD patients displayed a reduction of both FCR-TG and
CR-CE when compared with control subjects who did not
resent with angiographically detectable CAD. Such a
nding indicates that in those patients there is a reduction
f both intravascular lipolysis and removal of remnants of
he chylomicron-like emulsions. During the observation
eriod of 4.5  0.9 years, and despite secondary prevention
herapy, 33% of the followed CAD patients presented with
linically refractory angina and angiographic progression of
oronary lesions. When we compared the baseline data of
hese patients with those who displayed a stable clinical
volution, we found a significantly slower intravascular TG
ipolysis in those who had an unfavorable outcome. More-
ver, in a multivariate analysis, patients who had a DI below
he median displayed a three-fold higher risk of developing
clinically refractory angina than those with the DI above
he median. This finding is consistent with data from statin
linical trials, suggesting that post-statin-treatment levels of
lasma TGs predict the risk of cardiovascular disease (22).
herefore, we may conclude that the persistence of a slower
ntravascular TG lipolysis and, as a consequence, the ele-
ated circulating levels of TG-rich lipoproteins have a
linical impact in statin-treated patients and should be
onsidered as targets in future CAD prevention trials.
Increased levels of TG-rich lipoproteins have been dem-
nstrated to impair overall artery vasodilator capacity,
hereby reducing the post-obstructive reserve of blood flow
Table 3. Gensini Score and Plasma FCR of th
Patients Separated According to the Presence o
Non-S
n 10
Initial Gensini score 56 
Final Gensini score 68 
FCR cholesterol esters, min1 0.0078 
FCR of triglycerides, min1 0.0206 
Delipidation index 0.42 
Abbreviations as in Tables 1 and 2.23,24). Therefore, patients who presented with a lower ratef intravascular lipolysis should have been more sensitive to
he progression of obstructive coronary lesions. On the
ther hand, a reduced rate of remnant particle uptake
estimated from the measurement of FCR-CE) enhances
he residence time of TG-rich lipoproteins, namely VLDL
nd chylomicrons, in the arterial bed, thereby facilitating
heir subendothelial migration and favoring plaque progres-
ion (25,26). Because these two mechanisms are not mutu-
lly exclusive, the clinical aggravation observed in those
atients who displayed a more severely impaired intravas-
ular lipolysis may possibly result from the combination of
hese two mechanisms. Nevertheless, our current findings
an support only the mechanisms related to the progression
f coronary lesions.
onclusions. We presently demonstrate that the DI, the
et rate of intravascular TG catabolism from chylomicron-
ike emulsions, represents a significant and sensitive predic-
or of clinical progression of CAD in statin-treated patients.
herefore, our findings support the concept that TG-rich
ipoproteins, VLDL, chylomicrons, and their remnants are
mplicated in the pathophysiology of atherosclerosis and
ighlight the key relationship between intravascular TG
ipolysis and progression of CAD.
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